Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience to Participate in May Investment and Medical Conferences
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.